Page 2 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
P. 2

Program Faculty





               Program               Scott North                                      Srikala Sridhar
               Chairs                Cross Cancer Institute                           University Health Network
                                     Edmonton, Alberta                                Toronto, Ontario


               Program               Peter Black                                      Tracy Stockley
               Faculty               University of British Columbia                   University Health Network
                                     Vancouver, British Columbia                      Toronto, Ontario



                                     Pierre Karakiewicz
                                     Centre Hospitalier de l'Université de Montréal (CHUM)
                                     Montreal, Quebec



                 This program is also possible by the contribution of the GURC working group, a multidisciplinary working
                 group who drafted a management algorithm for advanced urothelial carcinoma in 2019 that includes
                                      st
                 newly approved 1 Line anti-PD-L1 therapies, emerging anti-FGFR and anti-Nectin 4 therapies and
                 required biomarker testing of PD-L1 expression levels and FGFR gene alterations.
   1   2   3   4   5   6   7